Health
SOPHiA GENETICS and MD Anderson Announce Strategic Collaboration to Accelerate AI-Driven Precision Oncology
SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration that unites SOPHiA GENETICS' AI-powered analytics with MD Anderson's clinical and scientific expertise to accelerate data-driven cancer care through new tools that can accurately analyze, interpret and translate diagnostic results into clinical practice.
About this update from Sophia Genetics Sa
[{"type":"text","content":"BOSTON and HOUSTON, Jan. 7, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration that unites SOPHiA GENETICS' AI-powered analytics with MD Anderson's clinical and scientific expertise to accelerate data-driven cancer care through new tools that can accurately analyze, interpret and translate diagnostic results into clinical practice.","length":493,"tagName":"p"},{"type":"image","alt":"SOPHiA GENETICS Logo (PRNewsfoto/SOPHiA GENETICS)","displaySize":"","headline":null,"caption":"SOPHiA GENETICS Logo (PRNewsfoto/SOPHiA GENETICS)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":267,"url":"https://media.zenfs.com/en/prnewswire.com/7af8bf13f8f939ef861dc0027929881b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/n6kFaeXBXi.jQBj8QTEY9A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ3MTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/7af8bf13f8f939ef861dc0027929881b","width":400,"height":267}},"href":"https://mma.prnewswire.com/media/1673202/SOPHiA_GENETICS_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"As part of the collaboration, MD Anderson and SOPHiA GENETICS are launching a series of research and development programs and co-developing an advanced next-generation sequencing oncology test. Built on the advanced AI algorithms of the SOPHiA DDM™ Platform, the new co-developed test aims to translate complex multimodal data into actionable insights with greater speed and scale. MD Anderson researchers will tap SOPHiA GENETICS' AI technologies to create bioinformatics pipelines that enable clinicians to rapidly interpret complex RNA-sequencing data to guide diagnosis and treatment for patients with cancer.","length":617,"tagName":"p"},{"type":"text","content":"Donna Hansel, M.D., Ph.D., Division Head of Pathology and Laboratory Medicine at MD Anderson, said: "Cancer research has evolved rapidly, and we have more health data available than ever before. Our collaboration with SOPHiA GENETICS reflects how our lab is evolving and integrating advanced analytics and AI to better interpret complex molecular information. This collaboration will expand our ability to translate high-dimensional data into insigh...